CLOUDBREAK PHARMA(02592.HK): IND Application for Novel Drug CBT-358 Completes Safety Review by US FDA
NewTimeSpace News: On 17 July 2026,CLOUDBREAK PHARMA(02592.HK) issued an announcement that the US FDA has finished the safety review of the IND application for novel drug CBT-358 and has no objections to the proposed clinical trials.
The announcement states that CBT-358 is a new addition to the Group’s product pipeline. It is a combination drug integrating perfluorinated alkane and transient receptor potential vanilloid 8 (TRPV8) agonist, indicated for the treatment of dry eye disease.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CLOUDBREAK PHARMA INC. (02592.HK): Bank Account of Subsidiary Frozen, Involving Approximately RMB 2.55 Million
- LUNG FUNG GROUP(02290.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 269.1 million, YoY increase of 57.89%
- LUNG FUNG GROUP(02290.HK) closed 9.93% lower on Jun 15, the Hang Seng Specialty Retail Sector saw divergent trends
- Lung Fung Plunges 45.75% on Listing Debut, Closing at HK$2.81
- Lung Fung Tumbles Over 15% on Debut, Last at HK$4.4
